Saving your money for next purchases
Lartruvo(olaratumab)奥拉木单抗
On October 19, 2016, the U.S. Food and Drug Administration (FDA) approved Lartruvo (ocaratumab) in combination with doxorubicin for the treatment of patients who cannot be cured by radiation therapy and surgery, but whose histological classification is suitable for the use of anthracyclines. Advanced soft tissue sarcoma (STS) in adults.
Share:
Products
Our offers
Delivery – when you want and anywhere
A huge selection of best products
Health Classification
Let us work together to protect precious health
